Analysts said the deal shows Roche’s long-term strategy for its sequencing technology is “a clinical box for running NGS kits, similar to with their prior success in IVD kits.”
Roche inks deal for rights to Freenome cancer tests outside US
Analysts said the deal shows Roche’s long-term strategy for its sequencing technology is “a clinical box for running NGS kits, similar to with their prior success in IVD kits.”